ABT-702

CAT: 0804-HY-112482-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-112482-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
ABT-702 is a potent, orally active, and selective adenosine kinase (AK) inhibitor with an IC50 of 1.7 nM. ABT-702 shows >1300-fold selectivity for AK over other biological targets, including cyclooxygenases-1 and -2. ABT-702 attenuates inflammation in diabetic retinopathy by increasing free adenosine levels. ABT-702 shows analgesic and anti-inflammatory effects in vivo. ABT-702 can be used for diabetic retinopathy research[1][2][3].
CAS Number
[214697-26-4]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Adenosine Kinase; Adenosine Receptor
Related Pathways
GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling
Applications
COVID-19-immunoregulation
Field of Research
Neurological Disease; Inflammation/Immunology
Purity
99.61
Solubility
DMSO : 25 mg/mL (ultrasonic)
Smiles
BrC1=CC=CC(C2=C3C(N)=NC=NC3=NC(C4=CC=C(N5CCOCC5)N=C4)=C2)=C1
Molecular Formula
C22H19BrN6O
Molecular Weight
463.33
Precautions
H302, H315, H319, H335
References & Citations
[1]Jarvis MF, et al. ABT-702 (4-amino-5- (3-bromophenyl) -7- (6-morpholinopyridin-3-yl) pyrido[2, 3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties: I. In vitro characterization and acute antinociceptive effects in the mouse. J Pharmacol Exp Ther. 2000 Dec;295 (3) :1156-64.|[2]Parkinson FE, et al. The Effect of Endogenous Adenosine on Neuronal Activity in Rats: An FDG PET Study. J Neuroimaging. 2016 Jul;26 (4) :403-5.|[3]Elsherbiny NM, et al. ABT-702, an adenosine kinase inhibitor, attenuates inflammation in diabetic retinopathy. Life Sci. 2013 Jul 30;93 (2-3) :78-88.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Popular Products